Vitamin K factor levels in warfarinised, bleeding or Dr Alexis Frangoulides,Dr 13/STH/178 Approve Dr. Krishna Badami Observational non-bleeding patients with John Pearson,Dr Mark Smith high or in-range INR Pharyngeal Mis-sequencing 13/STH/179 Provisionally approve following Neurologic Miss Kristin Lamvik Observational Impairment CDHB Research Office,Jan 13/STH/18 Approve 116428 (Zoster-039) Dr Andrew Butler Intervention Adams,COO Phase 3 Accelerated BEP 13/STH/180 Approve Dr Garry Forgeson Dr Kenneth Clark Intervention Filaggrin mutations in atopic 13/STH/187 Provisionally approve Professor Peter Hull Intervention dermatitis in Māori -Revised Assessment of the trial drugs ACH-0143102 and 13/STH/188 Approve Dr Christian Schwabe Auckland Clinical Studies Ltd Intervention ACH-0142684, when taken by healthy men and women The Familial Rheumatic 13/STH/189 Approve Dr Nigel Wilson Dr Rachel Webb Intervention Heart Disease Study Phase II Clinical Study Toric 13/STH/194 Provisionally approve Model Series ZXT and Dr Dean Corbett doctor neil murray Intervention Model XRA03 Assessment of the investigational Hepatitis C drug VX-135 when taken by adult patients with Mild or Professor Edward Auckland Clinical Studies 13/STH/197 Approve Intervention Moderate Liver Impairment. Gane Ltd,Chris Taylor, CCST Assessment of VX-135 and Daclatasvir taken with or without Ribavirin, whe High Concentration Oxygen 13/STH/200 Approve Dr Janine Pilcher Intervention in COPD Quantitative swallowing 13/STH/202 Approve measures in normal Dr Anna Miles Observational subjects Multi-electrode Radiofrequency Renal 13/STH/22 Approve Dr Scott Harding Trial White Intervention Denervation System Feasibility Study.
13/STH/178 Approve Vitamin K factor levels in warfarinised, bleeding or non-bleeding patients with high or in-range INR Dr. Krishna Badami Dr Alexis Frangoulides,Dr John Pearson,Dr Mark Smith Observational 13/STH/179 Provisionally approve Pharyngeal Mis-sequencing following Neurologic Impairment Miss Kristin Lamvik Observational 13/STH/18 Approve 116428 (Zoster-039) Dr Andrew Butler CDHB Research Office,Jan Adams,COO Intervention 13/STH/180 Approve Phase 3 Accelerated BEP Dr Garry Forgeson Dr Kenneth Clark Intervention 13/STH/187 Provisionally approve Filaggrin mutations in atopic dermatitis in Māori -Revised Professor Peter Hull Intervention 13/STH/188 Approve Assessment of the trial drugs ACH-0143102 and ACH-0142684, when taken by healthy men and women Dr Christian Schwabe Auckland Clinical Studies Ltd Intervention 13/STH/189 Approve The Familial Rheumatic Heart Disease Study Dr Nigel Wilson Dr Rachel Webb Intervention 13/STH/194 Provisionally approve Phase II Clinical Study Toric Model Series ZXT and Model XRA03 Dr Dean Corbett doctor neil murray Intervention 13/STH/197 Approve Assessment of the investigational Hepatitis C drug VX-135 when taken by adult patients with Mild or Moderate Liver Impairment. Assessment of VX-135 and Daclatasvir taken with or without Ribavirin, whe Professor Edward Gane Auckland Clinical Studies Ltd,Chris Taylor, CCST Intervention 13/STH/200 Approve High Concentration Oxygen in COPD Dr Janine Pilcher Intervention 13/STH/202 Approve Quantitative swallowing measures in normal subjects Dr Anna Miles Observational 13/STH/22 Approve Multi-electrode Radiofrequency Renal Denervation System Feasibility Study. Dr Scott Harding White Intervention Trial